UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Ef icacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, Mass., May ...

BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference call, participant ...

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024 (ESCMID, formerly ECCMID), which is taking place April ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer and Founder Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Eric Joseph - ...

Fourth Quarter and Full Year 2023 Financial and Business Update February 28, 2024 June 2020 NASDAQ: AVIR DISCLAIMERS Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies ...

Exhibit 99.1 Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board (DSMB) Planned for 1H'24 with Topline Results Expected 2H'24 Conference Call at 4:30 pm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 | --- | --- | |---------------------------------------------------------------------------------------------------------|------ ...

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients in Monotherapy Arm; First Interim Analysis by the Independent Data Safety Monitoring Board (DSMB) Expected in March 2024 BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv ...

Third Quarter 2023 Financial and Business Update November 8, 2023 DISCLAIMERS Forward-Looking Statements This presenta,on contains “forward-looking statements” within the meaning of the Private Securi,es Li,ga,on Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expecta,ons and assump,ons regarding the future of our business, future plans and strategies, our clinical results and other future condi ...